These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1518440)

  • 1. Proceedings of the workshop, "Practical approaches to the diagnosis and treatment of acromegaly".
    Liuzzi A; Sobrinho LG; Besser GM
    Metabolism; 1992 Sep; 41(9 Suppl 2):87-90. PubMed ID: 1518440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Sandostatin in acromegaly.
    Sassolas G
    Metabolism; 1992 Sep; 41(9 Suppl 2):39-43. PubMed ID: 1518432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic ketoacidosis: an unusual presentation of acromegaly.
    Dosi RV; Patell RD; Shah PJ; Joshi HK
    BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23761570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for dopamine agonists in the treatment of acromegaly.
    Jaquet P
    J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
    [No Abstract]   [Full Text] [Related]  

  • 8. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallstones in acromegalic patients undergoing different treatment regimens.
    Schmidt K; Leuschner M; Harris AG; Althoff PH; Jacobi V; Jungmann E; Schumm-Draeger PM; Rau H; Braulke C; Usadel KH
    Clin Investig; 1992 Jul; 70(7):556-9. PubMed ID: 1356530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of pituitary adenoma].
    Chanson P
    Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
    Sadoul JL; Thyss A; Freychet P
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus statement: benefits versus risks of medical therapy for acromegaly.
    Acromegaly Therapy Consensus Development Panel
    Am J Med; 1994 Nov; 97(5):468-73. PubMed ID: 7977436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide.
    Jones SL; Patchett S; Anderson JV; Farthing MJ; Besser GM; Wass JA
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):683-7. PubMed ID: 8736269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.